Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts Proactive uses images sourced from Shutterstock Bank lifts 2026 core earnings per share estimate 2% to $10.30 after first-quarter beat, sees positive risk-reward into late-year readouts Citi has raised its 2026 core earnings per share forecast for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) by 2% to $10.30 following a first-quarter beat and maintained its buy rating, arguing that risk-reward is positive ...